Topical Sulfasalazine and Oral Lichen Planus

• Status: Active, not recruiting
• Trial end date: 2023-11-20
• Target enrollment: 0
• Participant gender: All

Summary

Oral lichen planus (OLP) is a chronic inflammatory disease that affects the mucosal membrane. T-cell mediated damage against the mucosal epithelial cells is implicated in the pathogenesis of OLP, although the exact mechanism is unknown.

Sulfasalazine is extensively used in inflammatory bowel disease and is effective on immune-related inflammatory disease such as Crohn's disease, rheumatoid arthritis, and Behcet's disease. In spite of its effectiveness, the anti-inflammatory mechanism is not clearly understood.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Treatments: Sulfasalazine

Criteria

Inclusion Criteria:

• - Patients with 30-65 years old

• Patents with atrophic OLP

Exclusion Criteria:

• - Smokers

• pregnant or lactating ladies and

• Patients under topical or systemic steroids during the last two months

• Patients using lichenoid reaction-inducing drugs,

• Patients with positive hepatitis C virus (HCV) antibodies, diabetes and hypertension

• Patients having amalgam filling adjacent lesions will not also be included